Pfizer (PFE) Has a Cost-Reset and Pipeline Platform Bigger Than the Patent-Cliff Label

[ad_1] Pfizer (PFE) is often summarized as a large drug company trying to manage through patent losses and the post-COVID comedown. Its latest primary disclosures suggest the story is becoming more nuanced than that label. The more durable investment question…






